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The concept of phage therapy exists in the history and it has been ignored for a long time, but the 
consequence of drug resistance in pathogen bacteria has forced the forgotten kingdom of phage therapy to 
be re-explored. However, for the successful implementation and acceptance of phage therapy worldwide, 
the number of factors need to be addressed. In pharmacology of phage therapy, pharmacodynamics is a 
straightforward concept, on the other hand, owing to the unique feature of phages to replicate and their 
high sensitivity, pharmacokinetics is rather complex. In this review, we have discussed pharmacokinetics 
and some recent advances in delivery systems as to achieve the therapeutically effective concentrations 
of phage in their activated form.
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INTRODUCTION
Bacterial resistance against antibiotics has 
considerably peaked in recent years; the menace of 
resistance has given birth to a new range of extended 
spectrum pathogens. The failure of antibiotic and 
chemotherapy for eradication of bacteria has forced 
scientists to look for alternative biological methods. One 
such approach is the use of lytic bacteriophages against 
pathogen bacteria. Felix d’Hérelle, the discoverer of 
bacteriophages, first introduced the idea of phage therapy 
in the beginning of the 20th century (Sulakvelidze, 2005). 
However, the initial trials of phage therapy produced 
inconsistent results to be considered over antibiotics. Even 
though, some US pharmaceutical companies produced 
some commercial phage products in 1930s. Subsequently, 
the Soviet Union developed phage therapy against 
diseases like diarrhea and wound infections (Sulakvelidze, 
Alavidze, Morris, 2001). In Russia, several phage 
formulations are now being sold as registered medicine.
Phage therapy to combat bacterial infections is 
garnering attention for the second time in 100 years, but 
solid clinical support for its widespread use is still lacking. 
Before proper human clinical trial of phage therapy 
can be considered, there are a number of issues that are 
considered necessary to be addressed (Knoll, Mylonakis, 
2014). There are multiple factors that direct the therapeutic 
efficacy of phage therapy, for example, for convenient oral 
application; the phage must endure gastrointestinal route. 
Furthermore, phage should stay for a sufficient period of 
time and reach the infected tissue with high enough titer 
to achieve its lytic activity. Moreover, for safety, phage 
particles should not impose any side effects and must not 
carry any virulence gene, as they might get transferred to 
the target host.
The process of using phages for therapy is 
conceptually simple; although, along with the simplicity 
comes the consequences of a certain degree i.e. complex 
pharmacokinetics. This complexity is the phages’ ability 
to replicate their number, which is a result of antibacterial 
activity, precisely where target bacteria are present. As 
with any antimicrobial agent, the key step is to reach 
bacterial targets in enough loads to ensure that a minimum 
active concentration is achieved. This can be attained 
either through the direct application of phages to the 
infection site or via systemic delivery (Chan, Abedon, 
Loc-Carrillo, 2013).
Phage therapy pharmacokinetics
There is a handful of data that entails pharmacology 
of bacteriophage therapy, with a very few that emphasize 
on the pharmacokinetics of phage therapy. Pharmacology 
deals with the drug and body interactions, it is subdivided 
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in pharmacokinetics-body’s impact on drug- and 
pharmacodynamics-drugs impact on the body.
Pharmacokinetics accounts for a drug’s ability 
to reach sufficient concentrations in the locality 
of targeted tissues, as it is very important to bring 
about the pharmacodynamic effects of the drug. 
This pharmacokinetics summarizes into absorption, 
distribution, metabolism and excretion. Absorption is 
drug movement into the blood. From the blood the drug 
is transported to the body tissues this phenomenon is 
known as distribution. Once reached the target tissues, 
the drug is metabolized and modified into its active 
form, the last step is excretion of drugs from the body. 
All these pharmacokinetic features play their role in both 
increasing and reducing drug densities. For example, 
both absorption and distribution result in the decrease 
in drug densities owing to drug dilution, which at the 
same time might increases drug density in the particular 
body organ (Abedon et al., 2011). Depending upon the 
pharmacokinetics different means of drug delivery are 
adopted. The delivery route of a drug is selected on a 
number of factors; a) target tissue, b) sensitivity of drug 
to body enzymes, immunity, pH etc) drug in take routine, 
d) patient’s convenience.
In phage therapy, metabolism can work two ways; 
either inactivation of phage particles due to contact with 
the immune system or activation followed by replication 
of phages. Moreover, excretion results in decreased 
drug densities, the other way round, it can serve to 
increase phage concentration in organs like kidney and 
bladder, which may prove therapeutically beneficial 
(Vandenheuvel, Lavigne, Brüssow, 2015).
Whatever the case may be, the success of phage 
therapy depends on enough phage generations in the 
locality of the target to bring about the eradication of 
pathogen bacteria from the body. The increase in phage 
concentration to sufficient densities can be attained by 
two means. Firstly, with in situ replication, that is called 
active treatment, or as a result of pharmacologically 
conventional dosing, the passive treatment. The ways of 
rising phage concentration must be adequately stout so 
that they compensate the mechanism of phage reduction. 
The goal is thus to achieve minimum phage concentration 
at the target site, that is necessary for the desired levels 
of bacterial eradication. Also, worth mentioning is the 
necessity for phage preparations to be adequately purified 
(e.g., to remove bacterial debris). Such purification should 
be substantial (e.g., to remove most bacterial components, 
including endo-toxins), particularly when phages are to 
be delivered directly to an animal’s systemic circulation 
(Chan, Abedon, Loc-Carrillo, 2013).
Recently, the turn back to phage therapy has led 
the scientists to evaluate the pharmacokinetic efficacy 
of phage therapy. One such investigation was done in 
Phage Therapy Center at the Institute of Immunology and 
Experimental Therapy, the Polish Academy of Sciences. 
Scientists have examined the estimated cost of treating 
staphylococcal infection in which good clinical outcome 
of the bacteriophage therapy was shown. classically, the 
phages are delivered orally and/or locally in the form of 
phage lysates (Międzybrodzki et al., 2007). Moreover, the 
problem of phages to leave the blood stream and reach the 
infected tissues can be avoided by phage constructs with 
tissue-specific peptides, it will help the phages to reach the 
targeted organs (Górski et al., 2015).
Phage formulation is another important aspect 
of governing effective pharmacokinetics. Different 
formulation strategies are employed to increase the 
stability of phages. The no of active phages in a formulation 
is directly proportional to the efficacy of treatment. The 
table I summarize recent formulation strategies for the 
phage preparation.
Routes of administration
Var ious  s tud ies  have  been  conduc ted  on 
bacteriophage therapy to investigate the delivery routes, 
most studied being the parenteral and oral route of 
administration and both of them are systemic. On the 
other hand, non-systemic routes or local phage delivery 
systems are being investigated. The use of phage lysate 
for prevention of biofilm on medical equipment is also 
studied.
The varied concepts of pharmacokinetics – 
requirement for phage to penetrate the target bacteria, the 
accomplishment of adequate phage concentration in the 
locality of the target, and ample antibacterial action against 
the target – are worth considering when treating various 
infections in both animal models and humans.
Bacteriophages via parenteral delivery 
In phage therapy, parenteral delivery has proven 
to be the most successful of all delivery regimes; this 
success is explained by the maximum distribution and 
bioavailability of the administered phages.
A study was conducted on mice compromised by 
burn injury and subsequently infected by Psedumonas 
aeruginosa, the infected mice were treated with phage 
cocktail containing three different P. aeruginosa phages. 
Phages were given by three delivery routes; intramuscular, 
intravenous and intrasubcutaneous. The comparative 
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efficacies of these delivery routes were measured showing 
that the intravascular route provided the most significant 
defense against the infection (up to 87%). Moreover, the 
dosage quantity of given phage cocktail was also important 
in attaining improved pharmacokinetics, the high dosage 
of phages was more effective (McVay, Velásquesz, Fralick, 
2007).
Phage movement from one body section to another 
can greatly hurdle effective therapy. The parenteral and 
oral dosing primarily results in blood circulation. The 
absorption is expected to be more proficient through the 
parenteral route, i.e. there is a probability of less phage 
loss in parenteral delivery as compared to oral delivery. 
With oral dosing, phages must endure and pass the 
gastrointestinal zone, both of which are not the simple 
course of action. On the other hand, topical application 
minimizes associated losses of absorption and distribution, 
enhancing antibacterial activity of phages. Instillation, i.e. 
directly injecting phages in infection sites also minimizes 
the losses, though it is more restrained than topical 
application (Figure 1). (Abedon, 2015).
Similarly, another study, using Liposomes as a 
delivery vehicle for phage for the first time, used the 
intraperitoneal (IP) route of administration to explain the 
therapeutic and prophylactic potential of bacteriophage 
in a mouse model of lobar pneumonia caused by K. 
pneumoniae (Singla et al., 2015).
A similar study conducted previously, in which 
Bacteremia was induced in mice by IP injection of a strain 
of vancomycin-resistant Enterococcus faecium. A single IP 
injection of phage strain ENB6 was administered after 45 
min of infection. The survival rate was shown to be 100%. 
It was concluded that, when administered intravenously, 
phages can be efficient at clearing local infection and can 
be distributed and absorbed throughout the body (Biswas 
et al., 2002).
Most of the studies using P. aeruginosa delivered 
via the IP route suggested that the phages were rapidly 
distributed to the tissues and were delivered for a 
longer period of time than phages administered via the 
intrasubcutaneous or intramuscular route.
Bacteriophages via oral delivery 
Bacteriophage delivery through oral administration 
suggests its success in treating gastrointestinal infection 
and, in rare cases systemic infections. The pathogen 
bacteria, which is located in the gut is mainly accessible 
TABLE I - Phage formulation strategies
Formulation strategy Phage type Use Reference 
Liquid/ suspension ZF40, ZF49, Phage T4, BFC-1 phage cocktail.
Wound dressing, injectable, 
food additives and nebulizers. 
(Borie et al., 2009; Golshahi 
et al., 2008; Hoe et al., 2013; 
Merabishvili et al., 2009; 
Merabishvili et al., 2013)
Solid; Powdered, 
microencapsulation, 
KS14, N-1, S-204, Sh-1, 
KS-41, D3, F2, F-9, Felix01, 
cocktails
Inhalable powder, bandages, 
tablets, pills
(Hoe et al., 2013; Matinkhoo 
et al., 2011; Ohtake et al., 
2010; Vandenheuvel et al., 
2013)
Cream, oil-water emulsion Staphylococcus phage K Can be used as a topical, ointment
(Esteban et al., 2014; 
O’Flaherty et al., 2005)
PEGylated Felix01 Injectable (Veronese, Pasut, 2005)
Amino acid substitution Agro1, Agro2, Agro3, Agro4, W60 Injectable 54
FIGURE 1 - Route of Administrations and pharmacokinetics.
M. I. Qadir, T. Mobeen, A. Masood 
Braz. J. Pharm. Sci. 2018;54(1):e17093Page 4 / 9
to orally applied phages. However, there are drawbacks of 
the oral delivery system; primarily it’s the deactivate ion of 
bacteriophages by the acidic environment of stomach. The 
sensitivity to the acidic environment varies for different 
bacteriophages, for some deactivation may occur. Hence, 
there is a need for the characterization of bacteriophage 
individually.
The gastric acid neutralization is done with the 
administration of some “stomach acid neutralizing agent” 
like sodium bicarbonate or bicarbonated mineral water 
(Qadir, 2015). Phages may be given orally three times a day 
before eating, as the PH is slightly less acidic at this time.
Some orally applied phages are absorbed into 
the circulation system. However, it depends on the 
characteristics of each individual phage (Oliveira et 
al., 2009). Some phages reside inside the gut lumen, 
they are also absorbed through the intestinal walls. The 
underlying mechanism of the viral translocation remain 
unclear, it is recommended that the number of factors 
control bacteriophage passage through intestinal walls, 
for example, phage concentration, capsid protein’s specific 
sequences for interaction with the intestinal cell membrane 
and its interaction with immune cells within the gut.
For combating the problem of deactivation many 
preventive strategies can be applied. One such method is 
microencapsulation, for example, bacteriophage Felix O1 
was microencapsulated in alginate-chitosan microsphere. 
This encapsulation appreciably increased the acidic 
endurance of phage under laboratory conditions designed 
to replicate in the pig gastrointestinal tract (Ma et al., 2008). 
Recent encapsulation strategies are aimed at 
providing a delivery technology with improved efficacy of 
bacteriophage in oral application. Enteric polymers have 
been demonstrated to offer effective protection for bacteria 
against in vitro simulated gastric conditions; likewise, they 
might be used for the phage encapsulation.
Phage cocktail is another method to effectively 
deliver bacteriophages via oral administration. In an 
investigation, phage cocktail consisting of SP15, SP21 
and SP22 bacteriophages was used against a strain of E. 
coli, with the most successful administration route being 
a daily oral dose of phages (Tanji et al., 2005).
Hence, studies show that bacteriophage can be 
absorbed efficiently into systemic circulation through oral 
administration. Nonetheless, absorption via oral delivery 
depends on the individual characteristics of each phage 
as well.
Local delivery of phages
The local delivery of phages is one of the successful 
administration regimes, and several reports are present 
in literature, most of them focusing wound healing. 
There has been development of hydro-gel and saturated 
formulations of bacterio-phages for wound healing. It has 
greatly increased the phage therapy’s success in topical 
applications. Locally, phages can be applied on infected 
areas in the form of moist dressing (Qadir, 2015).
A commercially successful example of topical 
product is the Phagebioderm®, it was developed by the 
Eliava Institute, Georgia. This formulation specifically 
targets P. aeruginosa, S. aureus and Streptococcus spp. It 
is a cocktail of antibiotics and bacteriophages saturated 
in stabilized hydrogel arrangement for topical application 
(Markoishvili et al., 1999). Currently, local phage 
therapy has also focused on other areas i.e. otic and oral 
applications.
Topical administration of phages
In topical form, the bacteriophage has been effective 
for the treatment of skin ailments. A study has been 
reported using bacteriophages to decrease the infection 
of chicken skin by Salmonella and Campylobacter spp. 
The MOI of phages were assessed i.e. the effect of the 
ratio of phage particles to bacterial cells. Phages were 
applied at two different MOI, one at relatively higher MOI 
then other. The investigation showed that the efficiency 
of phage treatment was dependent on phage quantity. By 
increasing the MOI, increased bacterial eradication was 
observed (Goode, Allen, Barrow, 2003).
A recent report investigated the efficacy of phages 
against natural healing agents (aleovera and honey). The 
K. pneumoniae B5055-induced burn wound infection 
was treated with topical application of Klebsiella-specific 
phage Kpn5, on the other hand, with aleovera and honey. 
A survival rate of up to 96.66% observed with phage 
treatment in comparison to the death rate of 83.34% in 
the second group on the second day post treatment. One 
interesting finding was that the treatment with high titre of 
phage resulted in a long term solution to the infection and 
the low titre was ineffective, hence sufficient concentration 
of phages are crucial for the successful treatment (Kumari, 
Harjai, Chhibber, 2010).
Octic administration of phage
Data is available from clinical trials of bacteriophage 
therapy in chronic otitis caused by an extended spectrum 
strain of P. aeruginosa. The patients studied with an ear 
infection of P. aeruginosa. They were randomly divided 
into two groups, one receiving a single dose of Biophage-
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PA® and the second receiving placebo; the phages were 
given via octic administration. The patients followed up 
at 7, 21 and 42 days after treatment. It was shown that 
the administration of this topical bacteriophage mixture 
successfully killed P. aeruginosa in the ear and improved 
the clinical manifestation of ear infectivity (Wright et al., 
2009). A latest study, reporting clinical trial on canine for 
the treatment of P. aeruginosa otitis with bacteriophage 
cocktail, holds similar assures. Hence, this topical 
bacteriophage formulation is a potential candidate to be 
conveniently and effectively used against P. aeruginosa 
otitis in dogs (Hawkins et al., 2010).
Furthermore, phages are used in the form of 
suspension (Drops) for application to eye, middle ear and 
nasal mucosa (Qadir, 2015).
Dental phage administration
Number of papers and patent filing reports focus 
on the use of phages in combating dental infections. 
An investigation was carried out to assess the effect of 
bacteriophage on the viability of Enterococcus faecalis 
(ATTC 29212) in human dental roots. The teeth were 
divided in five groups, all were given different conc. of 
bacteriophages. A substantial reduction in bacterial growth 
was observed in all groups, which indicates the ability 
of phages to inhibit bacterial growth in teeth tubules. 
Hence phage therapy can be considered an alternative 
for root canal infection, which is otherwise intractable by 
conventional endodontic therapy (Paisano et al., 2004).
Nebulizer inhalation of bacteriophage
The most recent advances in the field of phage 
therapy have been inhalation technologies. In view of 
the success of bacteriophage therapy in both local and 
systemic applications, using bacteriophages to fight 
lung infections look promising. The development of 
modern inhalation and process technologies has allowed 
great advances in this field. Recently, nebulizers have 
been introduced to deliver bacteriophages to the lungs. 
A study focused on the efficiency of nebulizer delivery 
and the particle-size distribution of droplets (Golshahi et 
al., 2008). The nebulizer was shown to be successfully 
delivered the phage particles to the lungs. Moreover, 
further examination of in-vitro delivery of bacteriophages 
using the inhalation formulation of dry powder was done 
by the same group of scientist for treatment of cystic 
fibrosis pulmonary infections (Golshahi et al., 2011).
Another study was done indicating in-vivo efficacy 
of phage therapy for Burkholderia cepacia lung infections. 
A mouse model of severe respiratory tract infection was 
used; the effect of treatment with a single phage strain on 
bacterial load and lung inflammation was examined. Mice 
were administered, either by intranasal inhalation or by IP 
injection. However, Bacterial concentration, macrophage 
inflammatory protein 2 (MIP-2) and tumor necrosis factor 
α (TNF-α) levels, were significantly reduced in the lungs 
of mice treated with IP-administered phages as compared 
to the inhalational administration (Carmody et al., 
2010).A recent study suggests that P. aeruginosa isolated 
from the lungs of cystic fibrosis patients may become 
more susceptible, over the course chronic infections, to 
unassociated phages (Friman et al., 2013)
Many studies investigated the phage therapy against 
Pseudomonas aeruginosa in cystic fibrosis patients (James 
et al., 2015; Saussereau et al., 2014). The main element 
highlighted is the prospective of bacteriophage therapy 
in cystic fibrosis patients through inhalation. Certainly, 
the nebulizer route of administration is chosen for cystic 
fibrosis patients (Hraiech, Brégeon, Rolain, 2015).
Instillation of phages
A case study recently reported the treatment of a 67-
year old woman through instillation of phage formulation 
to the bladder. The patient was hospitalized and 20 ml 
Pyophage #051007 was instilled directly into the bladder 
for 10 days with 12 h gap, with the catheter fasten for 
half an hour after each instillation. The data indicated 
that bacteriophage infection was self-sustaining and self-
limiting, with the phage decreasing in number alongside 
the viable target organisms in which they replicated 
(Khawaldeh et al., 2011).
Elimination
After intraperitoneal administration, the level of 
bacteriophages decreased rapidly in first 8 to 12 hours and 
then gradually decreased and eventually disappeared in 
three days, depicts a pattern just like of two-compartmental 
model. The initial phase of the rapid decrease from 8 to 12 
hours (considered as alpha-phase) is due to distribution of 
phages to the organs and second phase (considered as beta 
phase) is due to elimination of phages (Uchiyama et al., 
2009). Although, the kinetics of blood clearance have had 
not been well described. So, for further development in 
therapeutic efficacy, information on bacteriophage blood 
kinetics is one of the most important criteria to determine 
optimal therapeutic approach.
Within 2 to 4 hours, a single oral dose results in the 
absorption of phages into the blood stream and to inner 
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organs in10 hours (Sulakvelidze et al., 2001). According 
to the data available, phages reside in human body and 
circulating system for a substantial time period. It was 
determined that reticulo-endothelial system is involved 
in elimination of bacteriophages from the human body. 
However, the possible role of innate immunity on 
elimination of bacteriophages is not clear.
CONCLUSION
Phage therapy is a promising alternative for the 
inadequacy of antibiotics and their ever-decreasing 
effectiveness. It is evident, from a vast amount of 
research on phage therapy against various bacterial 
diseases, that phage provides a stronger shield against 
stubborn resistant pathogen bacterial strains. They 
were assumed to be therapeutic due to their bactericidal 
activity by replication within the target host; this unique 
pharmacokinetic property of being self-replicating drug 
gives it a preference over other antibiotics and chemical 
drugs. Moreover, many phages have been isolated against 
these extended spectrum strains and patented. The 
different delivery routes are effective depending upon 
the target tissues or organ. For example, the oral phage 
delivery is useful for the treatment GI tract infections, for 
skin infection, the topical phage application is a suitable 
and pulmonary bacterial disease can be efficiently treated 
with the inhalation of phage nebulizer. The most effective, 
in terms of therapeutic advantage, is the parenteral route 
of administration, as it provides direct distribution and 
maximum absorption. However, there has been a little 
data available on the pharmacokinetic profiling of phage 
formulations that are being used or are waiting for 
approval. The pharmacokinetic factors like formulation 
and concentration are well elaborated in literature; on 
the other hand, convenient and effective administrative 
routes require to be explained through further research. 
Furthermore, to benefit the full from tiny phage particles 
the factors like kinetics of blood clearance must to be 
addressed.
TABLE II - Administration routes of phage therapy adapted in different pre-clinical and case study in humans
Administration route Against Results References
Intramuscular Meningitis in calves and E. coli septicaemia in chickens 
 Significant protection against 
E. coli
(Barrow, Lovell, Berchieri, 
1998)
Intravenous
Local and systemic disease 
caused by Vibrio vulniﬁcus 
and S. aureus in animals
Phage treatment was radically 
reduced inflammation due to 
infection
(Abedon et al., 2011) 
(Capparelli et al., 2007)
intra-peritoneally lethal Staphylococcus aureus infection in mice
S. aureus -induced lethality 
Suppressed (Matsuzaki et al., 2003)
Subcutaneous
 Lung abscesses in 
rabbits and bronchiectasis 
Staphylococcus aureus, 
Proteus, and Streptococci
92% survival was reported





gastrointestinal infections and 
and rare cases of systemic 
infections
Titres of E. coli were 
significantly reduced
(Tanji et al., 2005)
Topical administration
Skin infection. 
K. pneumoniae induced burn 
wound infection in mice
Up to 90 % survival rate as 
compared to control group
(Kumari, Harjai, Chhibber, 
2010)
Octic route
chronic otitis infection 
of extended spectrum P. 
aeruginosa
P. aeruginosa counts were 
significantly lower in the 
phage-treated group
(Wright et al., 2009)
Dental route
Enterococcus faecalis 
infection human dental 
Roots
Reduce bacterial growth and 
number in root canal (Paisano et al., 2004)
Inhalation Pseudomonas Staphylococcus and lung infections
50% reduction in required 
ongoing antibiotic treatment
(Golshahi et al., 2008; 
Kvachadze et al., 2011)
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